[Telangiectatic osteogenic sarcoma]

Area of Science:

• Pediatric Oncology
• Orthopedic Oncology
• Skeletal Tumors

Background:

• Telangiectatic osteosarcoma (SOT) is a rare and aggressive bone cancer.
• Early diagnosis and effective treatment are crucial for pediatric patients.

Purpose of the Study:

• To report on the clinical presentation, treatment, and outcomes of children diagnosed with telangiectatic osteosarcoma.
• To analyze the diagnostic process and therapeutic interventions for SOT in a pediatric cohort.

Main Methods:

• Retrospective case series of 6 pediatric patients with SOT.
• Review of clinical data, including age, tumor location, diagnostic procedures, chemotherapy regimens, surgical interventions, and patient outcomes.
• Pre-operative chemotherapy with Cisplatin and Adriablastine administered to all patients.

Main Results:

• Average patient age was 7.8 years; tumors were located in the proximal or distal femur.
• Average symptom duration before diagnosis was 8.6 weeks; 50% required two biopsies for diagnosis.
• All patients experienced rapid tumor growth and pathological fractures. Surgical interventions included mutilating procedures and endoprosthetic replacement. One patient developed lung metastases.
• Two patients are alive, but their current medical status is unknown.

Conclusions:

• Telangiectatic osteosarcoma in children presents with aggressive characteristics, including rapid growth and pathological fractures.
• Multimodal treatment including chemotherapy and surgery is necessary, but outcomes remain challenging.
• Further research is needed to improve diagnostic accuracy and therapeutic strategies for pediatric SOT.